F-1/A: Beroni Group Limited Files Amendment for Proposed Nasdaq IPO

Beroni Group Limited, an Australian biopharmaceutical company, has filed an amendment to its registration statement for a proposed initial public offering on the Nasdaq Capital Market.

Summary

• Beroni Group Limited, an Australian holding company with global biopharmaceutical operations, has filed an amendment to its Form F-1 registration statement with the SEC.
• The company is pursuing an IPO of its ordinary shares and aims to list on the Nasdaq Capital Market under the symbol BRNI.
• Beroni Group operates through subsidiaries in the US, Australia, China, Hong Kong, and Japan, focusing on anti-cancer drugs, cell therapies, infectious disease detection, and e-commerce sales of pharmaceutical products.
• The company completed a 4:1 reverse stock split on November 24, 2023.
• The majority of Beroni's principal businesses are located and conducted outside China, although a significant portion of its revenues are derived from China.
• The company intends to use the net proceeds from the offering primarily for clinical trials of its PENAO cancer drug and gamma delta T-cell therapy.
• The offering includes an underwriter's option to purchase up to an additional 15% of the ordinary shares.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced public company reporting requirements.
• The company faces risks associated with doing business in China, including regulatory uncertainties and potential government intervention.
• The company's auditor, UHY Haines Norton, has included an explanatory paragraph in their report regarding the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is pursuing an IPO and has a diversified business model, it also faces significant financial challenges and regulatory risks. The auditor's going concern warning is a major concern.

Positives

• The company has a diversified business model with operations in multiple countries.
• The company is developing a pipeline of innovative product candidates addressing immuno-oncology and treatment of infectious diseases.
• The company has established strategic alliances to conduct clinical development, manufacturing, and commercial capabilities.

Negatives

• The company's auditor has included an explanatory paragraph in their report regarding the company's ability to continue as a going concern.
• The company faces risks associated with doing business in China, including regulatory uncertainties and potential government intervention.
• The company has incurred significant losses in recent years.
• The company is dependent on its ability to raise additional financing.

Risks

• The company's auditor has included an explanatory paragraph in their report regarding the company's ability to continue as a going concern.
• The company faces risks associated with doing business in China, including regulatory uncertainties and potential government intervention.
• The company is dependent on its ability to raise additional financing.
• The company may be subject to investigations by competent regulators, fines or penalties, ordered to suspend our relevant operations and rectify any non-compliance, be prohibited from engaging in relevant business or conducting any offering.
• The company faces uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.
• The company may be exposed to liabilities under the Foreign Corrupt Practices Act and Chinese anti-corruption laws.

Future Outlook

The company expects a number of important clinical and commercial milestone events to occur over the next 2 years, including Phase II clinical trial of PENAO, Phase I clinical trial of Gamma Delta T Cell therapy, development of a medical treatment for COVID-19, commencement of clinical study of Dendritic Cells (DC) Vaccine Therapy, and commercial-scale production for the viral detection kit developed by Columbia University targeting the global markets.

Industry Context

The announcement reflects the ongoing trend of biopharmaceutical companies seeking access to capital markets for funding research and development activities, particularly in the areas of oncology and infectious diseases. The company's focus on the Chinese market aligns with the growing importance of China in the global pharmaceutical industry.

Comparison to Industry Standards

• The company's reliance on contract manufacturing is a common practice in the pharmaceutical industry, particularly for smaller companies.
• The company's focus on clinical trials in Australia and China reflects a strategy to leverage cost-effective clinical trial environments and access to large patient populations.
• The company's pipeline of product candidates is comparable to other small-cap biopharmaceutical companies, with a focus on high-growth areas such as immuno-oncology and infectious diseases.
• The company's financial performance is weaker than industry standards, with significant losses and reliance on external funding.

Legal Proceedings

• A claim for RMB1.4 million compensation was lodged by the deceased estate of a shareholder against Beroni Tianjin, which was dismissed by the Chinese court.

Related Party Transactions

• The company has engaged the services of Asia Invest Partners Pty. Ltd, owned by director Peter Yap Ting Wong, for financial and tax affairs management.
• The Group CEO, Jacky Boqing Zhang has provided a loan to Beroni Group Limited for working capital needs.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of new shares and convertible notes.
• Shareholders face risks associated with the company's ability to continue as a going concern.
• Employees may benefit from the company's growth and expansion, but also face risks associated with the company's financial challenges.
• Customers may benefit from the company's development of new and innovative products, but also face risks associated with the company's ability to deliver on its promises.

Next Steps

• Obtain Nasdaq listing approval.
• Commence Phase II clinical trials for PENAO in Australia and China.
• Advance gamma delta T-cell therapy through Phase I and II clinical trials in China and Japan.
• Develop a medical treatment for COVID-19 based on single-domain antibody technology.
• Commence clinical study of Dendritic Cells (DC) Vaccine Therapy.
• Embark on commercial-scale production for the viral detection kit developed by Columbia University targeting the global markets.

Key Dates

Keywords

IPO, Beroni Group, biopharmaceutical, Nasdaq, clinical trials, PENAO, gamma delta T-cell therapy, reverse stock split, China, regulatory risks